



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Arthur Zaks  
Serial No: 10/764,857 Art Unit: Unassigned  
Filed: 26 January 2004 Examiner: Unassigned  
Title: METHOD FOR INDUCING PAIN RELIEF USING IMIDAZO[1,2-A]PYRIDINE DERIVATIVES  
Docket No: 763510-3

18 November 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.  
No fee or statement is required.

§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- The statement as specified in 37 CFR §1.97(e) set out below; OR
- The fee of \$ 180.00 under 37 CFR §1.17(p).

       §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

       §1.97(e) The undersigned Attorney hereby states that:

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

No fee is believed to be due in filing this paper. The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

*Alan J. Grant* 11/18/04

Alan J. Grant, Esq.

Date

Respectfully submitted,

*Alan J. Grant*

Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Arthur Zaks  
Serial No: 10/764,857 Art Unit: Unassigned  
Filed: 26 January 2004 Examiner: Unassigned  
Title: METHOD FOR INDUCING PAIN RELIEF USING IMIDAZO[1,2-A]PYRIDINE DERIVATIVES  
Docket No: 763510-3

18 November 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL**

Sir:

Applicant herewith files the following papers:

1. Information Disclosure Statement;
2. Form 1449 (1 sheet);
3. Copies of 4 references; and
4. Self-addressed, Postage paid, return receipt postcard.

No fees are believed due in filing these papers. If any fees are due, the Commissioner is authorized to charge payment of any additional fees under 37 C.F.R. 1.27 or credit any overpayment to Deposit Account No. 03-0678.

Serial No. 10/764,857  
Filed: 26 January 2004

**FIRST CLASS CERTIFICATE**

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Alan J. Grant 11/18/04  
Alan J. Grant, Esq. Date

Respectfully submitted,




Alan J. Grant, Esq.  
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,  
CECCHI, STEWART & OLSTEIN  
Six Becker Farm Road  
Roseland, NJ 07068  
Phone: 973-994-1700  
Fax: 973-994-1744

Form PTO-1449

## INFORMATION DISCLOSURE STATEMENT



Atty. Docket:

763510-3

Serial No.

10/764,857

Applicant: Arthur Zaks

Filing Date: 26 January 2004

Group:

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	5,767,117	16 June 1998	Moskowitz			18 November 1994
	B1	6,379,649	30 April 2002	Katsifis			6 April 1999
	C1	4,382,938	10 May 1983	Kaplan			21 October 1981

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	D1	WO 04/066930	12 August 2004	PCT			<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
	E1						<input type="checkbox"/> Yes <input type="checkbox"/> No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	F1	Bourguignon, in Peripheral Diazepine Receptors, Ch. 3, pp. 59-85 (Academic Press, 1993)
	G1	Almirante et al, J. Med. Chem. Vol. 12, pp. 122-126 (1969)
	H1	Almirante et al, J. Med. Chem. Vol. 8, pp. 305-312 (1965)
	I1	Langer et al., Pharmacology, Biochemistry & Behavior, Vol. 29, pp. 763-766 (1988)
	J1	
	K1	
	L1	
	M1	
	N1	
	O1	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.